Analysis for EW

📈 Growth & Financial Trajectory

Over the 8 quarters, Revenues grew from about $1.3859B (2024-Q2) to $1.741B (2026-Q2), a roughly 25% rise. Net income to parent declined from about $365M in 2024-Q2 to $241.4M in 2026-Q2, reflecting volatility, though the longer-term top-line trend remains positive.

💰 Margins & Cash Flow

Gross margins have been consistently high (Gross margins in the mid-to-upper 70s percent, with several quarters near 85%), indicating strong product economics. Operating income remained robust in most periods, suggesting favorable leverage. Net cash flow from operating activities was positive in every quarter and, on a continuing basis, around several hundred million, supporting solid liquidity. Cash flow from investing and financing fluctuated, but overall net cash flow was positive in several quarters.

🛡️ Balance Sheet & Liquidity

Balance sheet remains resilient: Current assets exceed Current liabilities by a wide margin (current ratio 3-4x). Equity base stands around $10-11B with manageable liabilities.

⚠️ Key Drivers & Risks

• Drivers: robust adoption of Edwards Lifesciences' heart-valve technology; favorable reimbursement dynamics
• Risks: quarterly earnings volatility; valuation sensitivity given strong revenue growth but uneven net income